EASL 2011: Liver Disease Progression in HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 12 April 2011 14:50
- Written by Liz Highleyman
Liver stiffness measured by FibroScan is a good predictor of liver cancer, end-stage liver disease or death among people with HIV/HCV coinfection, researchers reported as EASL 2011.
EASL 2011: BMS-790052 + Pegylated Interferon/Ribavirin Works Well for First HCV Treatment
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 12 April 2011 14:11
- Written by Liz Highleyman
About 90% of treatment-naive genotype 1 hepatitis C patients achieved sustained response at 12 weeks post-treatment using the experimental HCV protease inhibitor BMS-790052 plus pegylated interferon/ribavirin, researchers reported at EASL 2011. 
HBV Genotype Predicts HBeAg Seroconversion on Tenofovir
- Details
- Category: EASL 2011
- Published on Tuesday, 12 April 2011 09:51
- Written by Liz Highleyman
Chronic hepatitis B patients with HBV genotype A and lower HBsAg levels at baseline were more likely to experience HBeAg seroconversion during treatment with tenofovir (Viread), researchers reported at EASL 2011. 
EASL 2011: BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 12 April 2011 14:02
- Written by Matt Sharp
Most prior non-responders with HCV genotype 1 achieved sustained response with a quadruple combination containing 2 experimental agents plus pegylated interferon/ribavirin, and nearly 40% did so using only the 2 oral drugs -- BMS-790052 and BMS-650032 -- researchers reported at EASL 2011.
Immune-Based Therapy GS-9620 Shows Promise for Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 12 April 2011 03:38
- Written by Liz Highleyman
Gilead's GS-9620, an experimental TLR7 agonist, stimulated interferon production and activated B-cells and T-cells in laboratory and human studies, and was active against hepatitis B and a related virus in monkeys and woodchucks, researchers reported at EASL 2011.
More Articles...
- EASL 2011: First Sustained Response Data for HCV Polymerase Inhibitor Mericitabine
- EASL 2011: Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug
- EASL 2011: Telaprevir Improves HCV Cure Rates Regardless of IL28B Status
- Telaprevir Combo Works for HCV Patients with Prior Unsuccessful Treatment
Web Design and Development by